New Guidelines for Mpox Testing in Pacific Island Laboratories Released: Essential Updates for 2025

On January 15, 2025, new interim laboratory guidance was issued for laboratories in Pacific Island countries and territories regarding mpox (formerly known as monkeypox) virus testing. This crucial update supersedes the previously released guidance from September 2024, addressing evolving protocols and safety measures.

Key Updates You Need to Know:

1. Shipping Protocols Enhanced: Clinical samples sent to the Victorian Infectious Diseases Reference Laboratory (VIDRL) for mpox testing can now be shipped as Category B biological substances (UN 3373). This change simplifies the logistics of transporting these samples while ensuring compliance with safety regulations.

2. Improved Testing Guidance: The latest guidelines include additional instructions for using the Cepheid Xpert Mpox cartridge, which enhances the accuracy and efficiency of mpox testing. This update is expected to significantly improve testing turnaround times.

3. Broader Testing Recommendations: New recommendations for additional non-mpox testing have been integrated into the guidance. This expansion acknowledges the importance of comprehensive diagnostic capabilities in health facilities across the region.

4. In Vitro Diagnostics Reference: A newly added link to the World Health Organization’s Emergency Use Listing for in vitro diagnostics provides access to the most current approved tests, ensuring that laboratories adhere to global standards of care.

These updates are vital for healthcare providers and laboratory staff involved in mpox surveillance and response efforts in the Pacific region. The ongoing evolution of testing protocols reflects the global health community's commitment to combatting infectious diseases and ensuring public safety.

Stay tuned for more updates as the situation regarding infectious diseases continues to evolve, and be ready to implement these crucial guidelines in your laboratory practices!